Parsons Capital Management Inc. RI increased its position in Celgene Co. (NASDAQ:CELG) by 67.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 61,965 shares of the biopharmaceutical company’s stock after purchasing an additional 24,970 shares during the period. Parsons Capital Management Inc. RI’s holdings in Celgene were worth $5,846,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of CELG. BlackRock Inc. lifted its position in Celgene by 2.8% in the 4th quarter. BlackRock Inc. now owns 53,650,909 shares of the biopharmaceutical company’s stock worth $3,438,486,000 after buying an additional 1,459,100 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in Celgene by 9,691.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 16,495,997 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 16,327,522 shares in the last quarter. Geode Capital Management LLC lifted its position in Celgene by 8.6% in the 4th quarter. Geode Capital Management LLC now owns 9,942,267 shares of the biopharmaceutical company’s stock worth $636,179,000 after buying an additional 787,638 shares in the last quarter. Norges Bank purchased a new stake in Celgene in the 4th quarter worth approximately $484,390,000. Finally, Clearbridge Investments LLC lifted its position in Celgene by 9.2% in the 3rd quarter. Clearbridge Investments LLC now owns 7,133,588 shares of the biopharmaceutical company’s stock worth $638,385,000 after buying an additional 598,631 shares in the last quarter. 74.47% of the stock is owned by hedge funds and other institutional investors.
Shares of CELG opened at $94.22 on Monday. The firm has a market capitalization of $66.18 billion, a P/E ratio of 12.38, a PEG ratio of 0.43 and a beta of 1.71. Celgene Co. has a one year low of $58.59 and a one year high of $95.44. The company has a current ratio of 2.23, a quick ratio of 2.12 and a debt-to-equity ratio of 3.21.
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.45 by $0.10. The firm had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.01 billion. Celgene had a net margin of 30.10% and a return on equity of 125.23%. The business’s quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.05 EPS. On average, research analysts expect that Celgene Co. will post 10.02 EPS for the current fiscal year.
A number of equities research analysts have issued reports on CELG shares. Jefferies Financial Group downgraded shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 target price for the company. in a research report on Friday, February 1st. ValuEngine upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th. William Blair restated a “buy” rating on shares of Celgene in a report on Thursday, February 28th. Finally, Wells Fargo & Co cut their price target on shares of Celgene from $90.00 to $84.00 and set a “market perform” rating on the stock in a report on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $99.41.
In related news, Director Ernest Mario purchased 2,000 shares of the firm’s stock in a transaction on Tuesday, February 12th. The shares were bought at an average cost of $89.99 per share, for a total transaction of $179,980.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director James J. Loughlin sold 23,466 shares of the firm’s stock in a transaction on Thursday, February 7th. The stock was sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the completion of the sale, the director now owns 62,102 shares in the company, valued at $5,420,883.58. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: Google Finance Portfolio
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.